NCT03650400View on ClinicalTrials.gov

Pharmacokinetics, Safety and Tolerability of Fevipiprant Delivered Via a Once Daily Chewable Tablet in Children Aged 6 to < 12 Years With Asthma

PHASE2TerminatedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

May 1, 2019

Primary Completion Date

December 16, 2019

Study Completion Date

January 22, 2020

Conditions
Asthma
Interventions
DRUG

Fevipiprant

Chewable tablet

Trial Locations (6)

55402

Novartis Investigative Site, Minneapolis

65203

Novartis Investigative Site, Columbia

74136

Novartis Investigative Site, Tulsa

78006

Novartis Investigative Site, Boerne

78229

Novartis Investigative Site, San Antonio

79903

Novartis Investigative Site, El Paso

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY